Resolute Integrity DES is a leading product in the Medtronic Interventional Portfolio. Designed for increasingly complex clinical practice, Resolute Integrity DES is built to simplify your everyday challenges. Featuring the groundbreaking Integrity™ technology, Resolute Integrity DES delivers powerful performance.

- **DES Technology for Today + Tomorrow**
  - Unique Continuous Sinuwave Technology defines current performance and enables future innovations of CoreWire Technology, drug-filled stents and biodegradable stents

- **Rooted in Real-World Experience to Help Patients with Diabetes**
  - First FDA-approved DES for the treatment of CAD in patients with diabetes

- **Powerful Clinical Evidence to Address Challenging Cases**
  - More than 7600 patients studied, including a real-world patient population, and 2 million patients treated

---

**Resolute Integrity DES Product Ordering Information**

<table>
<thead>
<tr>
<th>Diameter (mm)</th>
<th>9</th>
<th>10</th>
<th>12</th>
<th>22</th>
<th>26</th>
<th>30</th>
<th>34</th>
<th>38</th>
<th>4</th>
<th>4.5</th>
<th>5</th>
<th>5.5</th>
<th>6</th>
<th>6.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length (mm)</td>
<td>38</td>
<td>40</td>
<td>42</td>
<td>52</td>
<td>54</td>
<td>56</td>
<td>60</td>
<td>64</td>
<td>80</td>
<td>90</td>
<td>100</td>
<td>110</td>
<td>120</td>
<td>130</td>
</tr>
</tbody>
</table>

---

**DES Technology for Today + Tomorrow**

Innovating for life.
AHEAD OF THE CURVE

Resolute Integrity DES is a leading product in the Medtronic Interventional Portfolio. Designed for increasingly complex clinical practices, Resolute Integrity DES is built to simplify your everyday challenges. Featuring the groundbreaking Integrity™ platform, Resolute Integrity DES delivers powerful performance.

- DES Technology for Today + Tomorrow
  - Unique Continuous Sinusoid Technology defines current performance and enables future innovations of CoreWire Technology, drug-filled stents, and biodegradable stents
  - When drug-eluting stents (DES) are used outside the specified indication, stent placement should only be performed at hospitals where emergency catheter-based treatments (including balloon dilatation) of the coronary artery are available and where emergency catheter-based treatments (including balloon dilatation) of the coronary artery are performed
  - Only physicians who have received adequate training should perform stent placement procedures
  - This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy

- Rooted in Real-World Experience to Help Patients with Diabetes
  - First FDA-approved DES for the treatment of CAD in patients with diabetes

- Powerful Clinical Evidence to Address Challenging Cases
  - More than 7,600 patients studied, including a real-world patient population, and 2 million patients treated

**MEDTRONIC INTERVENTIONAL PRODUCT PORTFOLIO**

<table>
<thead>
<tr>
<th>Diameter (mm)</th>
<th>2.50</th>
<th>2.75</th>
<th>3.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSINT25008UX/W</td>
<td>RSINT25012UX/W</td>
<td>RSINT25014UX/W</td>
<td>RSINT25018UX/W</td>
</tr>
<tr>
<td>RSINT25022UX/W</td>
<td>RSINT25026UX/W</td>
<td>RSINT25030UX/W</td>
<td>RSINT25034UX/W</td>
</tr>
<tr>
<td>RSINT27508UX/W</td>
<td>RSINT27512UX/W</td>
<td>RSINT27514UX/W</td>
<td>RSINT27518UX/W</td>
</tr>
</tbody>
</table>

For further information, please call and/or consult Medtronic at the toll-free number or website listed.

**RESOLUTE INTEGRITY™ ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM**

**DES Technology for Today + Tomorrow**

**Innovating for life.**
Resolute Integrity™ stent's continuous range of motion permits uniform response along the full stent length—simplifying navigation through challenging anatomies.

**DES Technology**
for Today + Tomorrow

Resolute Integrity DES and Resolute Integrity DES have treated 2 million patients around the world.

**Rooted in Real-World Experience**
to Help Patients with Diabetes

Rigorous data from more than 7600 patients studied, including a real-world patient population, support Resolute Integrity stent's safety and efficacy across the clinical spectrum. With no need for platform improvements, Resolute Integrity DES has treated 2 million patients around the world.

**US DIABETES PATIENTS HAVE:**

- 2-3X Risk of Death
- 30% of Target Lesion Revascularization
- 60% Risk of Major Adverse Cardiac Events

Medtronic is committed to treating these challenging patients and is proud to sponsor the American Diabetes Association’s “Make The Link” initiative.

**First FDA-Approved DES for the Treatment of CAD in Patients with Diabetes**

- RESOLUTE Pooled analysis showed low event rates in patients with diabetes

**RESOLUTE Pooled Analysis—Diabetic Subset at 12 Months**

- 0.5% (n=867)
- 0.3%
- Low 3.3% rates at 3.5% and 5% at 2.5%

**Powerful Clinical Evidence**
to Address Challenging Cases


Medtronic ADRS; 455-295-6500; Medtronic_ADRS@medtronic.com; 455-295-6500; medtronic.com

**SAFETY ASSURED**

Low 0.5% rates at 5 years

The BioLinx polymer showed minimal inflammation and allowed rapid and complete endothelial healing.

**Complex Cases**

- 3.9%
- Zero Incidence of OSA
- 100% procedural success
- 100% cohort survival

**First FDA-Approved Drug-Eluting Stent**

- Drug-coated delivery system
- Drug-coated balloon
- Drug-eluting stent
- Drug-coated balloon

**SAFETY ASSURED**

Low 0.5% rates at 5 years
RESOLUTE Pooled Analysis—Diabetic Subset at 12 Months

- **TLR**: 6.6
- **Non-Drug-Related Target Lesion Revascularization (TLR)**
- **Minimal Inflammation**
- **Low TLR rate at 5 years**

**RESOLUTE Pooled Analysis**
- Low TLR rate at 5 years
- The BioLinx polymer showed minimal inflammation and allows rapid and complete endothelial healing

**RESOLUTE**
- US DIABETES PATIENTS HAVE:
  - 2-3X increase in TLR vs. bare metal
  - 30% of TLR in patients with diabetes
  - 60% of all TLR in patients with diabetes

**Medtronic is committed to treating these challenging patients and is proud to sponsor the American Diabetes Association’s “Make The Link” initiative.**

**RESOLUTE All Comers and RESOLUTE US trials were not specifically designed or powered for the endpoints shown above.**

**Safeguard Integrity with Resolute Integrity DES**
- Drug-coated stent technology
- Lower TLR rate at 5 years
- 0.5%

**CoreValve® in Ischemia**
- Advanced Catheter
- Export
- Aspiration

**Drug-Coated Technology**
- Resolute Integrity stent’s continuous range of motion permits uniform response along the full stent length—simplifying navigation through challenging anatomies.

**Powerful Clinical Evidence**
- Rigorous data from more than 7600 patients studied, including a real-world patient population, support Resolute Integrity stent’s safety and efficacy across the clinical spectrum. With no need for platform improvements, Resolute Integrity DES has treated 2 million patients around the world.

**Drug-Filled Stent Technology**
- Drug-coated stent technology
- Lower TLR rate at 5 years
- 0.5%

**Noncompliant Balloon**
- Drug-coated balloon technology
- Lower TLR rate at 5 years
- 0.5%

**Semicompliant Balloon**
- Drug-coated balloon technology
- Lower TLR rate at 5 years
- 0.5%

**Aspiration Advance™ Catheter**
- Advanced catheter technology
- Export
- Aspiration

**REVEAL LINQ™ Monitoring System**
- Cardiac
- Confida™

**TAVR System**
- CoreValve™
- Rooted in Real-World Experience
- to Help Patients with Diabetes

**Drug-Coated Stent Technology**
- Drug-coated stent technology
- Lower TLR rate at 5 years
- 0.5%

**Noncompliant Balloon**
- Drug-coated balloon technology
- Lower TLR rate at 5 years
- 0.5%

**Semicompliant Balloon**
- Drug-coated balloon technology
- Lower TLR rate at 5 years
- 0.5%

**Aspiration Advance™ Catheter**
- Advanced catheter technology
- Export
- Aspiration

**REVEAL LINQ™ Monitoring System**
- Cardiac
- Confida™

**TAVR System**
- CoreValve™
- Rooted in Real-World Experience
- to Help Patients with Diabetes

**Drug-Coated Stent Technology**
- Drug-coated stent technology
- Lower TLR rate at 5 years
- 0.5%
Resolute Integrity™ stent’s continuous range of motion permits uniform response along the full stent length—simplifying navigation through challenging anatomies.

US DIABETES PATIENTS HAVE:

- 2-3X reduced rate of late loss
- 30% of diabetes patients eligible for PCI
- 60% of diabetes patients eligible for PCI

Medtronic is committed to treating these challenging patients and is proud to sponsor the American Diabetes Association’s “Make The Link” initiative.

RESOLUTE Pooled Analysis was not specifically designed or powered for the endpoints shown above.

First FDA-Approved DES for the Treatment of CAD in Patients with Diabetes

RESOLUTE Pooled Analysis—Diabetic Subset at 12 Months

- Low TLR rate at 0.5% and 3.1% at 12 months

Rigorous data from more than 7600 patients studied, including a real-world patient population, support Resolute Integrity stent’s safety and efficacy across the clinical spectrum. With no need for platform improvements, Resolute Integrity DES has treated 2 million patients around the world.

SAFETY ASSURED

The BioLinx polymer showed minimal inflammation and allowed rapid and complete endothelial healing.

Compared to other DES, Resolute Integrity DES showed a significant reduction in late loss and late lumen loss.

RESOLUTE: Just the beginning...

Resolute Integrity DES and Resolute Integrity Zotarolimus-Eluting Stent showed:

- USPCI endpoints at 5 years
- USPCI endpoints at 1 year
- USPCI endpoints at 3 years
Resolute Integrity DES is a leading product in the Medtronic Interventional Portfolio. Designed for increasingly complex clinical practice, Resolute Integrity DES is built to simplify your everyday challenges. Featuring the groundbreaking Integrity™ platform, Resolute Integrity DES delivers powerful performance.

- DES Technology for Today + Tomorrow
  - Unique Continuous Sinusoid Technology defines current performance and enables future innovations of CoreWire Technology, drug-filled stents and bioabsorbable stents

- Rooted in Real-World Experience to Help Patients with Diabetes
  - First FDA-approved DES for the treatment of CAD in patients with diabetes

- Powerful Clinical Evidence to Address Challenging Cases
  - More than 7600 patients studied, including a real-world patient population, and 2 million patients treated

---

**MEDITRONIC INTERVENTIONAL PRODUCT PORTFOLIO**

- TOC
- PCI
- CARM
- APV

---

**Resolute Integrity DES Product Ordering Information**

<table>
<thead>
<tr>
<th>Diameter</th>
<th>Length (mm)</th>
<th>Diameter</th>
<th>Length (mm)</th>
<th>Diameter</th>
<th>Length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.50</td>
<td>RSINT25008UX/W</td>
<td>3.00</td>
<td>RSINT30009UX/W</td>
<td>3.50</td>
<td>RSINT35009UX/W</td>
</tr>
<tr>
<td>3.00</td>
<td>RSINT30012UX/W</td>
<td>3.50</td>
<td>RSINT35012UX/W</td>
<td>4.00</td>
<td>RSINT40009UX/W</td>
</tr>
<tr>
<td>3.50</td>
<td>RSINT35014UX/W</td>
<td>4.00</td>
<td>RSINT40012UX/W</td>
<td>4.50</td>
<td>RSINT45009UX/W</td>
</tr>
<tr>
<td>4.00</td>
<td>RSINT40015UX/W</td>
<td>4.50</td>
<td>RSINT45012UX/W</td>
<td>5.00</td>
<td>RSINT50009UX/W</td>
</tr>
<tr>
<td>4.50</td>
<td>RSINT45015UX/W</td>
<td>5.00</td>
<td>RSINT50012UX/W</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**DES Technology for Today + Tomorrow**

For further information, please call or visit Medtronic at the toll-free number or website listed.

www.medtronic.com

Medtronic, Inc.
400 First Street West
Santa Rosa, CA 95403

Tel: 888.283.7868
Fax: 888.283.7869

Innovating for life.